A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

Authors:
Rubio-Pérez L; Lázaro-Gorines R; Harwood SL; Compte M; Navarro R and 16 more

Journal:
Oncoimmunology

Publication Year: 2023

DOI:
10.1080/2162402X.2023.2205336

PMCID:
PMC10128431

PMID:
37114242

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Oncoimmunology

Abbreviation: Oncoimmunology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor ac…
Albu DI; Wolf BJ; Qin Y and 12 more (2024) - Transparency Score: 2/6
An oncogene regulating chromatin favors response to immunotherapy: Oncogene CHAF1A and immunotherap…
Ying L; Hu Z; Lu Y and 11 more (2024) - Transparency Score: 2/6
Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells.
Glöckner HJ; Martinenaite E; Landkildehus Lisle T and 5 more (2024) - Transparency Score: 3/6
Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8<sup>+</sup>T cell func…
Wei W; Tian L; Zheng X and 6 more (2024) - Transparency Score: 3/6
Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor …
Ramil CP; Xiang H; Zhang P and 10 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure statement M.C., R.N., and O.H. are all employees of Leadartis. L.A.-V. and L.S. are co-founders of Leadartis. The remaining authors declare no competing interests."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025